Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
PHASE3This is a prospective, 12-week, randomized, double-blind, placebo-controlle...
Location
UCLA DGSOM, UCLA Health, UCLA Semel Institute
An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects
PHASE1This is a single-center, open-label, non-randomized, single dose of 14C-NW-...
Location
Quotient Sciences
Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia
PHASE2This 4-week study will evaluate the safety, tolerability and preliminary ev...
Location
Behavioral Research Specialists, LLC